Abstract
PROUD-PV study is a phase III study to compare the efficacy and safety of the novel Ropeginterferon α-2b (AOP2014) versus Hydroxyurea (the current licensed therapy for this disease) in both HU naive and currently treated patients, diagnosed with Polycythemia vera.